Abstract
Eurycoma longifolia Jack (Tongkat Ali) has long been associated with male reproductive health, but its constituents have also been investigated for metabolic, inflammatory, anti-infective, osteogenic, and anticancer activities. This narrative review critically evaluates these non-reproductive findings, emphasizing constituent identity, mechanistic evidence, experimental reliability, pharmacokinetic exposure, and translational challenges. In hyperuricemic mice, eurycomanol reduces serum urate and increases urate clearance, accompanied by decreased hepatic phosphoribosyl pyrophosphate synthetase expression and changes in renal and intestinal urate-transporter expression. Recent studies report binding of eurycomanone to STAT3 and reversal of its renal protective effects by the STAT3 agonist ML115 in mice, as well as binding of 6α-hydroxyeurycomalactone to dengue virus NS5 RNA-dependent RNA polymerase. However, neither binding interaction has been established as necessary for the observed pharmacological effects. Protein synthesis inhibition by eurycomalactone also complicates interpretation of NF-κB reporter inhibition. Most evidence remains preclinical, and reported total plasma exposure to eurycomanone after oral administration in rats is lower than some nominally active in vitro concentrations, although this comparison does not establish target-site exposure or oral therapeutic infeasibility. Human trials of standardized extracts report changes in immune biomarkers and mixed quality-of-life, mood, and fatigue outcomes, without establishing efficacy for specific non-reproductive diseases. Safety assessment must integrate preparation-specific genotoxicity concerns identified by the European Food Safety Authority, a suspected liver-injury case, and a human study showing reduced propranolol exposure during co-administration with a water extract. These findings do not establish equivalent risks across preparations or purified constituents. Further progress requires chemically characterized preparations, validated molecular targets, exposure-informed efficacy studies, and preparation-specific safety and herb–drug interaction assessments.